ADAM28 (a disintegrin and metalloproteinase 28) is abundantly expressed by carcinoma cells in the human breast and non-small cell lung carcinomas, and plays a role in carcinoma cell growth and metastasis. Although Src is an inducer of ADAM28 gene expression through the PI3K/ AKT/mTOR and MEK/ERK pathways, direct transcriptional regulators for ADAM28 gene expression remain unknown. In this study, we performed the luciferase reporter assay and found that SOX4 (SRY-related HMG-box 4), an inducer of epithelial-mesenchymal transition (EMT), is a transcriptional activator for the ADAM28 gene. This activation required the SOX4-binding consensus sequence at the 5'-untranslated region of the mouse and human ADAM28 genes. Forced expression of SOX4 promoted the ADAM28 gene expression and migration in human breast and lung carcinoma cell lines. In the human breast and lung carcinoma tissues, ADAM28 and SOX4 were co-expressed at the invasive front of carcinoma cell nests. Our data demonstrate that SOX4 transactivates ADAM28 gene expression through direct binding to the ADAM28 promoter region and suggest the possibility that ADAM28 plays a role in invasion through SOX4-mediated EMT in the human breast and lung carcinomas.
ADAM28 is a member of the ADAM (a disintegrin and metalloproteinase) gene family, which is characterized by the presence of unique metalloproteinase and disintegrin domains in the molecules. 1, 2 Among the 21 human ADAM family members, 13 members exert proteinase activity to membrane and/or extracellular proteins, but the other eight members are non-proteolytic molecules. [1] [2] [3] Some of the proteolytic ADAM species such as ADAM10 and ADAM17 are endowed with the activity of shedding, the process by which ectodomains of the membrane-type cytokines or receptors are cleaved, resulting in production of soluble molecules. [4] [5] [6] ADAM28 can cleave several extracellular molecules such as insulin-like growth factor binding protein-3 (IGFBP-3), von Willebrand factor (VWF) and connective tissue growth factor (CTGF). [7] [8] [9] [10] Although ADAM28 is composed of prototype membrane-anchored ADAM28m and secreted isoform of ADAM28s, previous studies showed that both forms of ADAM28 are abundantly expressed in human malignant neoplastic tissues, including the breast carcinomas, 8 non-small cell lung carcinomas, 11, 12 head and neck carcinomas, 13 urinary bladder carcinomas 14 and chondrosarcomas. 15 In non-small cell lung carcinomas, the expression levels in the carcinoma tissues and concentrations of ADAM28 in the serum samples showed positive correlations with tumor cell proliferation, lymph node metastasis, carcinoma recurrence and clinical stage of the patients. 11, 13, 16 ADAM28 promotes breast carcinoma cell proliferation by reactivation of insulin-like growth factor I (IGF-I) by selective digestion of IGFBP-3 in the IGF-I/ IGFBP-3 complex, in which IGF-I activity is inactivated. 7, 8 ADAM28 also enhances lung metastasis by suppressing VWF-induced tumor cell apoptosis through digestion of VWF within blood vessels. 10 CTGF binds to vascular VEGF 165 angiogenic activity. 17 The digestion of CTGF in the VEGF 165 /CTGF complex by ADAM28 is known to lead to angiogenesis by releasing active VEGF 165 from the complex. 9 These studies have provided the data on the implication of ADAM28 for carcinoma cell proliferation and metastasis. Because of favorable roles of ADAM28 in tumor growth and metastasis, oncogenic signals were suspected to contribute to ADAM28 expression. Actually, we have demonstrated that Src induces ADAM28 expression in oncogene-transformed MadinDarby canine kidney epithelial cells and human carcinoma cell lines through the PI3K/AkT/mTOR and MEK/ERK pathways. 18 However, no or little information is available for transcription factors, which regulate ADAM28 gene expression. Recent studies have provided the data suggestive of the interactions between the signaling pathways of Src and SOX4 (SRY-related HMG-box 4), [19] [20] [21] which is a member of the C subgroup of SRY-related high mobility group (HMG) transcription factors.
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SOX4 is known to be a critical activator of the PI3K/AKT/mTOR pathway, [19] [20] [21] and Ingenuity Pathway Analysis has suggested that SOX4 may target ADAM10. 19 SOX4 is expressed in various tissues during development and plays a pivotal role in embryonic development and organogenesis. 22, 23 It is also overexpressed in various malignant tumor tissues including carcinomas of the lung, stomach, colorectum, liver, uterus, prostate and urinary bladder, melanoma, glioma and leukemia. 22 In most of these tumors, SOX4 acts as a pro-oncogenic factor, and its target genes include many pro-oncogenic molecules. 22, 23 SOX4 also promotes tumor cell proliferation by enhancing the Wnt signaling pathway, 24 and activates genes important for maintenance of stemness in glioma cells. 25 More recently, SOX4 was reported to be essential to epithelial-mesenchymal transition (EMT) by regulating the epigenetic modifier Ezh2. 26 Thus, all these data suggest the possibility that SOX4 transcription factor may be involved in ADAM28 gene expression, although no studies have been conducted for the role of this transcription factor in ADAM28 gene expression. In this study, we examined whether SOX4 activates ADAM28 gene expression by reporter assay, and disclosed, to the best of our knowledge, for the first time that SOX4 transactivates ADAM28 gene expression through direct binding to ADAM28 promoter region. We also found that ADAM28 and SOX4 are co-expressed at the invasive front of carcinoma cell nests in the human breast and lung adenocarcinoma tissues. Our results suggest that ADAM28 may be involved in carcinoma cell invasion through SOX4-mediated EMT of cancer cells.
MATERIALS AND METHODS

Plasmid construction
The mouse and human ADAM28 genomic DNA fragments were amplified by polymerase chain reaction (PCR) from the genomic DNA of C57BL/6-derived ES cells (TransGenicInc, Fukuoka, Japan) and MDA-MB231 cells, respectively, and subcloned into pGL3-Basic Vector (Promega, Madison, WI, USA). The mouse and human SOX4 DNA fragments were amplified from total-RNA of Ed17 mouse embryo and PC-9 cells by reverse transcription-PCR (RT-PCR), respectively. They were subcloned into pcDNA3 (Invitrogen, Carlsbad, CA, USA) with FLAG-epitope at the N-termini to generate mouse and human SOX4 expression vectors. All the inserts were fully sequenced to evaluate PCR fidelity.
Cell cultures and transfection
COS7, MCF-7 and MDA-MB231 cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and PC-9 cell line was from Immuno-Biological Laboratories (Gunma, Japan). COS7, MCF-7 and MDA-MB231 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. PC-9 cells were cultured in RPMI medium supplemented with 10% fetal bovine serum. They were transfected with plasmids using FuGENE6 Transfection Reagent (Roche, Basel, Switzerland) according to the manufacturer's instruction.
Reporter assay
COS7 cells were transfected with reporter constructs and SOX4 expression vectors. They were lysed with Passive Lysis Buffer (Promega) at 24 h after transfection. The relative luciferase activity was measured using Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instruction.
RT-PCR and quantitative real-time PCR (qPCR)
Total RNA was isolated using ISOGEN (Nippon Gene, Tokyo, Japan), and first-strand cDNA was synthesized with ReverTra Ace (TOYOBO, Osaka, Japan). RT-PCR was performed with ExTag (TaKaRa, Kusazu, Japan) by using the primers for 
GGCGACGCAAAAGAAGATGCG-3 (reverse).
Migration assay PC-9 cells and MCF-7 cells transfected with human SOX4 expression vectors or vectors alone (mock) were grown on confluence on six-well plates (BD Biosciences, Bedford, MA, USA) in the culture media containing 10% FBS and antibiotics. They were scratch-wounded with a blue pipette tip, and cell migration activity in the media containing 5 mM hydroxyurea (Sigma-Aldrich) was determined as described previously. 27 
Immunohistochemistry
Breast carcinoma (n ¼ 10) and lung adenocarcinoma (n ¼ 7) tissues were obtained from Keio University Hospital (Tokyo, Japan) at surgery from the patients with invasive ductal carcinoma of no special type and those with invasive lung adenocarcinoma, respectively. Subtypes of the lung adenocarcinomas, which were classified based on the predominant histological patterns according to the WHO classification, 28 were solid (n ¼ 3), papillary (n ¼ 3) and acinar (n ¼ 1) adenocarcinomas. All these patients received neither chemotherapy nor radiation therapy before operation. Paraffin sections of the formalin-fixed carcinoma tissues were dewaxed, autoclaved in 20 mM Tris-HCl buffer (pH 9.0). After treating with 0.03% of H 2 O 2 solution and then with 5% skim milk in 0.01% PBS, the sections were incubated with anti-SOX4 antibody (0.4 mg/mL; H-90) (Santa Cruz Biotechnology, Dallas, TX, USA), anti-ADAM28 antibody (2 mg/mL; 297-2F3), 8, 11 non-immune rabbit IgG (2 mg/mL; DAKO, Carpinteria, CA) or non-immune mouse IgG (2 mg/mL; DAKO). Then, they were incubated with horseradish peroxidase-conjugated polymer (Envision TM þ/ HRP, DAKO), and subsequently detected with 3,3 0 -diaminobenzidine. They were counterstained with hematoxylin. To examine the co-localization of SOX4 and ADAM28, paired mirror sections of the breast and lung carcinoma tissues were prepared and each section was subjected to SOX4 and ADAM28 immunohistochemistry analysis as described above. The study protocol, which complied with the principles outlined in the Declaration of Helsinki, was approved by the Keio University School of Medicine Ethics Committee (No 20140384). 
RESULTS
SOX4 activates ADAM28 reporter gene through binding to the SOX4-binging sites
Since SOX4-binding consensus sequence was found in the 5 0 -UTR of both mouse and human ADAM28 genes, we examined the possible involvement of SOX4 in the ADAM28 gene expression. As shown in Fig. 1a , SOX4 itself significantly enhanced ADAM28 reporter gene expression in the mouse À2000mA28 construct. To study the SOX4-responsive region, we generated a shorter construct, À300mA28, which includes about 300 bp of the 5 0 -UTR containing the SOX4-binding consensus sequence AA-CAAT of the mouse ADAM28 gene. 29 This construct showed SOX4-induced ADAM28 reporter gene expression (Fig. 1b) . We then tested whether the reporter gene expression is through specific binding of SOX4 to the motif by generating the mutant form of the À300mA28 (AACAAT ! GGTACC; À300mA28mt), and found that the À300mA28mt construct shows significantly reduced expression of the SOX4-induced reporter gene expression compared with the wild-type À300mA28 construct (Fig. 1c, d ), suggesting that mouse SOX4 promotes ADAM28 gene expression by binding to the ADAM28 5 0 -UTR.
We next examined whether human SOX4 also augments human ADAM28 gene expression. The human ADAM28 reporter construct hA28, which contains 1369 bp of human ADAM28 5 0 -UTR, was generated and the relative luciferase activity was examined. As shown in Fig. 2a , human SOX4 enhanced the ADAM28 reporter gene expression. The construct hA28 contained two potential SOX4-binding consensus sequences, AACAAT at À156 and ATTGTT at À91. 29 The mutant forms of hA28 (hA28mt1, hA28mt2 and hA28mt1þ2) were generated to examine the region responsible for SOX4 binding (Fig. 2b) . The hA28mt1 construct, which mutated in the first site at À156, slightly but significantly decreased the SOX4-induced reporter gene activity, and, the hA28mt2 construct, which mutated the second site at À91, also significantly reduced the activity (Fig. 2c) . The hA28mt1þ2 construct, the mutant form at both sites, reduced the activity to the level similar to that with the hA28mt2 construct, suggesting that ATTGTT at À91 is the critical site for SOX4-mediated human ADAM28 gene expression (Fig. 2c) .
Overexpression of SOX4 induces ADAM28 gene expression and promotes migration
To assess whether forced expression of SOX4 alters ADAM28 expression level, we transfected human cancer cell lines PC-9 and MCF-7 cells with the human SOX4 expression vectors and examined the mRNA expression of ADAM28 by RT-PCR and qPCR. The expression of two alternative spliced forms of ADAM28, namely ADAM28m and ADAM28s, was examined. As shown in Fig. 3a and b, forced expression of SOX4 in PC-9 cells significantly increased the expression of ADAM28m and ADAM28s expression. Under this condition, migration activity of PC-9 cells was significantly higher in the cells transfected with SOX4 expression vectors than in the mock transfectants (Fig. 3c) . On the other hand, transfection with the SOX4 expression vectors in MCF-7 cells, which showed negligible expression of ADAM28, 8 increased only the expression of ADAM28s ( Fig. 3d and e) . Migration assay showed significantly increased migration in the SOX4 transfectants compared to mock transfectants (Fig. 3f ).
SOX4 and ADAM28 are co-expressed at invasive front of the human breast and lung carcinoma tissues
We next examined the in vivo expression of SOX4 and ADAM28 in the human breast carcinoma and lung adenocarcinoma tissues. Surgical specimens of the invasive ductal carcinomas of no special type and invasive lung adenocarcinomas were immunostained with anti-SOX4 antibody and anti-ADAM28 antibody. As shown in Fig. 4a-d , SOX4 expression was found in both the cytoplasmic and nuclear components of the breast and lung carcinoma cells, but strong staining appeared to be present mainly in the nuclei of the carcinoma cells at the invasive front and/or those of the small carcinoma cell nests, suggesting the elevated SOX4 expression by the invading carcinoma cells. Overall nuclear staining of SOX4 in the carcinoma cells, except for those at the invasive front, was weak, probably due to the proteosomal regulation of the SOX4 protein. 30 Weak immunostaining of SOX4 was occasionally seen in the nuclei of lymphocytes infiltrated around carcinoma cells as previously reported. 31 ADAM28 expression was observed in majority of the breast and lung carcinoma cells, confirming our previous data. 8, 11 However, the carcinoma cells at the invasive front and/or those of the small carcinoma cell nests tended to show the stronger immunostaining for ADAM28 as compared to the carcinoma cells located in the center of tumor cell nests ( Fig. 4e and f) , whereas no or negligible immunostaining was obtained with non-immune IgG ( Fig. 4g and h ).
To analyze correlations between the immunohistochemical expression of SOX4 and that of ADAM28 in the breast and lung carcinoma cell nests, we compared the ratios of strongly positive carcinoma cells for SOX4 or ADAM28 to total carcinoma cells, and found that the SOX4-positive and ADAM28-positive cell ratios are significantly higher in the peripheral part of breast carcinoma cell nests than in the central part of the nests (Fig. 5a, b) . In the lung adenocarcinomas, similar correlations were obtained in the solid adenocarcinoma components (Fig. 5c, d ), which were present as a major or minor component in four out of seven lung adenocarcinoma cases, i.e. solid adenocarcinoma (3/3 cases), papillary adenocarcinoma (1/3 cases) and acinar adenocarcinoma (0/1 case). However, since the locus of invasive front in the papillary, acinar and lepidic components of the lung adenocarcinomas was difficult to determine, this analysis was not applicable for these subtypes of the lung adenocarcinomas. Immunostaining of SOX4 and ADAM28 in mirror sections demonstrated that SOX4 and ADAM28 are co-expressed by the breast carcinoma cells and solid lung adenocarcinoma cells at the invasive front (Fig. 6 ).
DISCUSSION
In this study, we have demonstrated that ADAM28 is a transcriptional target of SOX4, and these molecules are coexpressed by the carcinoma cells at the invasive front of the breast and lung carcinoma tissues. Since SOX4 is one of the master regulators of EMT, 26 up-regulation of ADAM28
by the action of SOX4 and their co-localization at the invasive front suggest that besides the role of ADAM28 in carcinoma cell proliferation, ADAM28 may be involved in carcinoma cell invasion and subsequent metastasis through EMT in the breast and lung carcinoma tissues.
Our previous study has shown that Src acts as an inducer for the ADAM28 gene expression in human carcinoma cell lines of the breast, lung, ovary, kidney and colon through its downstream PI3K/AKT and MEK/ERK signaling pathways. 18 In the present study, we have demonstrated by the experiments of reporter assay and forced expression that the gene expression of ADAM28 is up-regulated by the interaction of SOX4 with the promoter region of ADAM28. SOX4 has many target molecules and involves complex pathways for the expression of the target genes. 19, 22 Targeted disruption of SOX4 reduces survival of pro-B cells by increasing apoptosis through decreased phosphorylation of Src, indicating that Src is a downstream gene of SOX4. 20 In addition, genome-wide promoter analyses in prostate carcinoma cells and leukemic cells have demonstrated that potential SOX4 transcriptional targets include several pathways such as the PI3K/AKT pathway, 19, 21 which is one of the key pathways for Srcmediated ADAM28 expression. 18 Although molecular mechanisms on the cross-talk between SOX4 and Src remain to be clarified by further studies, it seems plausible to think that SOX4 and Src synergistically augment ADAM28 expression by amplifying signaling cascades such as the PI3K/AKT pathway.
Carcinoma cells at the invasive front commonly show EMT, 32, 33 which is crucial for cancer cells to acquire invasiveness and metastatic ability. 34, 35 EMT programs are complex and can be induced by various molecular, cellular and microenvironmental signals. 36, 37 Among them, SOX4
has been recently reported to play a central role in EMT and attracted attention as one of the master regulators in EMT. 26 In the present study, we showed nuclear immunostaining of SOX4 in the carcinoma cells located at the invasive front and/or the small cell nests sited in the breast and lung carcinoma tissues. On the other hand, Src is also known to induce EMT. 38 Therefore, both SOX4 and Src may be involved in EMT in the breast and lung carcinomas. One of the interesting findings in the present study is colocalization of SOX4 and ADAM28 at the invasive sites in the human breast and lung carcinomas. ADAM28 cleaves several substrates including IGFBP-3, 8 CTGF 9 and VWF. 10 Among them, the IGFBP-3 digestion by ADAM28 is notable, since this action leads to the release of active IGF-I from the IGF-I/ IGFBP-3 complex, in which IGF-I is inactivated by binding to IGFBP-3, 7 and all these players seem to be assembled in these carcinoma tissues. 39, 40 Emerging evidence has indicated that IGF-I signaling promotes the EMT process by both relocating b-catenin to the nucleus and inducing transcription factors required for EMT. 40, 41 Taken altogether, it is possible to speculate that SOX4-induced ADAM28 coordinately functions to maintain and/or enhance SOX4-mediated EMT at the invasive sites in the breast and lung carcinomas. However, this hypothesis remains to be demonstrated by further experimental and clinicopathological studies.
